Literature DB >> 27611114

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.

Stephen P Mulligan1,2, Christopher M Ward3,4, David Whalley3,5, Sarah N Hilmer3,6.   

Abstract

Entities:  

Keywords:  atrial fibrillation; chronic lymphocytic leukaemia; drug interactions; ibrutinib; stroke prophylaxis

Mesh：

Substances：

Year:  2016        PMID： 27611114     DOI： 10.1111/bjh.14321

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

Review 2.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 3.  Atrial Fibrillation and Cancer Patients: Mechanisms and Management.

Authors:  David L Madnick; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2022-08-17       Impact factor: 3.955

4.  How I treat cardiovascular complications in patients with lymphoid malignancies.

Authors:  Joerg Herrmann; Kristen B McCullough; Thomas M Habermann
Journal:  Blood       Date:  2022-03-10       Impact factor: 25.476

5.  Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.

Authors:  Sidra Khalid; Samin Yasar; Aariez Khalid; Timothy Pp Spiro; Abdo Haddad; Hamed Daw
Journal:  Cureus       Date:  2018-05-29

6.  High incidence of atrial fibrillation in patients treated with ibrutinib.

Authors:  Florian Baptiste; Jennifer Cautela; Yan Ancedy; Noémie Resseguier; Thérèse Aurran; Laure Farnault; Marion Escudier; Chloé Ammar; Mélanie Gaubert; Charles Dolladille; Jeremie Barraud; Michael Peyrol; Ariel Cohen; Franck Paganelli; Joachim Alexandre; Stephane Ederhy; Franck Thuny
Journal:  Open Heart       Date:  2019-05-08

7.  Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Authors:  Markus C Stühlinger; Ansgar Weltermann; Philipp Staber; Daniel Heintel; Thomas Nösslinger; Michael Steurer
Journal:  Wien Klin Wochenschr       Date:  2019-08-14       Impact factor: 1.704

Review 8.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

Review 9.  Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors:  Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 10.  Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.

Authors:  Maude Sestier; Christopher Hillis; Graeme Fraser; Darryl Leong
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.